UroGen Pharma (URGN) awards director RSUs and stock options

Rhea-AI Filing Summary

UroGen Pharma Ltd. director Cynthia M. Butitta received new equity awards as part of her compensation. She was granted 8,000 restricted stock units, each representing a right to receive one ordinary share. These RSUs will vest in equal quarterly installments over one year, so the award is earned gradually as service continues.

She was also granted stock options covering 10,000 ordinary shares at an exercise price of $34.99 per share, expiring on June 22, 2036. The option shares vest in equal quarterly installments over one year, aligning her incentives with long‑term shareholder value rather than reflecting any open‑market buying or selling.

Insights

Equity compensation analyst

Routine director equity grants align pay with long-term share performance.

Director Cynthia M. Butitta received equity awards consisting of 8,000 restricted stock units and options on 10,000 ordinary shares at an exercise price of $34.99. Both awards vest in equal quarterly installments over one year, conditioning value on continued board service.

These Form 4 entries reflect compensation grants, not open-market purchases or sales, so they carry limited signaling value about the director’s view of the stock. With the options expiring on June 22, 2036, her potential upside is tied to long-term share appreciation.

Subsequent company disclosures may detail additional equity awards or changes in director compensation structure, but this filing alone primarily documents standard, time-based vesting incentives.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider BUTITTA CYNTHIA M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right ot buy)	10,000	$0.00	$0.00
Grant/Award	Restricted Stock Unit	8,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right ot buy) — 10,000 shares (Direct); Restricted Stock Unit — 8,000 shares (Direct)

Footnotes (3)

1. F1. The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
2. F2. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
3. F3. The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.

Key Figures

Restricted stock units granted: 8,000 RSUs Stock options granted: 10,000 options Option exercise price: $34.99 per share +5 more

8 metrics

Restricted stock units granted 8,000 RSUs Equity award to director on June 22, 2026; each RSU for one ordinary share

Stock options granted 10,000 options Equity award to director on June 22, 2026

Option exercise price $34.99 per share Stock option grant covering 10,000 ordinary shares

Option expiration date June 22, 2036 Expiration of stock options granted to director

RSU vesting schedule Quarterly over 1 year RSUs vest in equal quarterly installments, subject to Continuous Service

Option vesting schedule Quarterly over 1 year Option shares vest in equal quarterly installments, subject to Continuous Service

RSU shares following transaction 8,000 derivative shares Total RSU-linked shares following the grant

Option shares following transaction 10,000 derivative shares Total option-linked shares following the grant

Key Terms

Restricted Stock Unit, Stock Option, Continuous Service, 2017 Equity Incentive Plan, +1 more

5 terms

Restricted Stock Unit financial

"The director received 8,000 restricted stock units as part of her equity compensation."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Stock Option financial

"She was also granted stock options covering 10,000 ordinary shares at an exercise price."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Continuous Service financial

"Vesting is conditioned on the director’s Continuous Service under the 2017 Equity Incentive Plan."

2017 Equity Incentive Plan financial

"Continuous Service is defined in the company’s 2017 Equity Incentive Plan governing these awards."

exercise price financial

"The stock options carry an exercise price of $34.99 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

What insider transactions did UroGen Pharma (URGN) report for Cynthia M. Butitta?

UroGen Pharma reported that director Cynthia M. Butitta received equity compensation grants, including 8,000 restricted stock units and stock options on 10,000 ordinary shares. These awards are time-vested and do not represent open-market buying or selling of URGN shares.

How many restricted stock units were granted to the UroGen Pharma director in this Form 4?

The director received 8,000 restricted stock units (RSUs). Each RSU represents a contingent right to receive one ordinary share of UroGen Pharma, vesting in equal quarterly installments over one year, subject to her continued service on the board during that period.

What are the terms of the stock options granted to the UroGen Pharma director?

The filing shows stock options covering 10,000 ordinary shares with an exercise price of $34.99 per share. These options vest in equal quarterly installments over one year and expire on June 22, 2036, tying potential value to long-term share performance.

Do the UroGen Pharma Form 4 transactions involve open-market purchases or sales of URGN stock?

No, the transactions reflect equity compensation grants, not open-market trades. The director received RSUs and stock options as awards, which vest over time. There are no reported open-market buys or sells in this Form 4 filing for URGN.

How do the RSUs granted to the UroGen Pharma director vest over time?

The 8,000 RSUs vest in equal quarterly installments over one year. Vesting is conditioned on the director’s Continuous Service under UroGen Pharma’s 2017 Equity Incentive Plan, meaning she must remain in service through each vesting date.

What does Continuous Service mean in the context of UroGen Pharma’s equity awards?

In this context, Continuous Service refers to the director remaining in an eligible service role under the 2017 Equity Incentive Plan. Both the option shares and RSUs vest only if she continues this service through the specified quarterly vesting dates over one year.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/24/2026 - 10:00 AM Accepted by SEC EDGAR 06/24/2026 - 10:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BUTITTA CYNTHIA M

(Last) (First) (Middle)

400 ALEXANDER PARK DRIVE

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right ot buy)	$34.99	06/22/2026		A		10,000		(1)	06/22/2036	Ordinary Shares	10,000	$0	10,000	D
Restricted Stock Unit	(2)	06/22/2026		A		8,000		(3)	(3)	Ordinary Shares	8,000	$0	8,000	D

Explanation of Responses:

1. The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer

3. The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.

	/s/ Jason D. Smith, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)